At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 856 enrolled
Drug / intervention
Experimental: Tralokinumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Asthma Inadequately Controlled on Inhaled Corticosteroid Plus Long-Acting β2-Agonist
In Brief
A Phase 3 clinical trial evaluating Experimental: Tralokinumab and Placebo for Uncontrolled Asthma. Completed, enrolled 856 participants across 234 sites in 13 countries.
Detailed Summary
A 52-Week, Multicentre, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents with Asthma Inadequately Controlled on Inhaled Corticosteroid Plus Long-Acting β2-Agonist
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUncontrolled Asthma
CountriesCanada, Chile, Czechia, Italy, Japan, Mexico, Philippines, Russia, South Africa, Taiwan, Ukraine, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJul 2014
Enrollment StartOct 2014
Primary CompletionMay 2017
Study CompletionSep 2017
TodayJul 2026
First PostedJul 18, 2014
Enrollment StartOct 30, 2014
Primary CompletionMay 10, 2017
Study CompletionSep 21, 2017
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 12.0 years ago
Interventions
Experimental: Tralokinumabbiological
Tralokinumab subcutaneous injection
Placeboother
Placebo subcutaneous injection